Literature DB >> 28127261

Smoking-related genitourinary cancers: A global call to action in smoking cessation.

Josh Gottlieb1, Cory Higley1, Roman Sosnowski2, Marc A Bjurlin3.   

Abstract

Smoking is a known modifiable risk factor in the development of genitourinary malignancies. Although the association has long been supported by numerous research studies, the impact of smoking cessation on the decreased risk of genitourinary malignancies is less well studied. PubMed databases were searched using the terms smoking, smoking cessation, bladder cancer, kidney cancer, prostate cancer, penile cancer, testicular cancer, their synonyms, and also targeted manual searches to perform a literature review in order to summarize the benefits of cessation on disease progression and patient outcomes including survival and morbidities. Our review yielded substantial evidence highlighting the improved outcomes observed in those diagnosed with bladder, renal, and prostate cancers. The risk of bladder cancer is reduced by up to 60% in those who were able to quit for 25 years and the risk of kidney malignancy was reduced by 50% in those who abstained from smoking for 30 years. A similar trend of reduced risk was observed for prostate cancer with those who quit for more than 10 years, having prostate cancer mortality risks similar to those that never smoked. Although the data were encouraging for bladder, renal, and prostate malignancies, there are comparatively limited data quantifying the benefits of smoking cessation for penile and testicular cancers, highlighting an opportunity for further study. The role of urologists and their impact on their patients' likelihood to quit smoking shows more than half of urologists never discuss smoking cessation upon diagnosis of a malignancy. Most urologists said they did not provide cessation counseling because they do not believe it would alter their patients' disease progression. Studies show urologists have more influence at changing their patients' smoking behaviors than their primary care physicians. The diagnosis of cancer may lead to a teachable moment resulting in increased smoking quit rates. Furthermore, implementing a brief 5-minute clinic counseling session increases quit attempts and quit rates. Diagnosis of genitourinary cancers and the following appointments for treatment provide a unique opportunity for urologists to intervene and affect the progression and outcome of disease.

Entities:  

Keywords:  Genitourinary malignancy; Risk reduction; Smoking; Smoking cessation

Year:  2016        PMID: 28127261      PMCID: PMC5260949          DOI: 10.3909/riu0729

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  37 in total

1.  Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies.

Authors:  P Brennan; O Bogillot; S Cordier; E Greiser; W Schill; P Vineis; G Lopez-Abente; A Tzonou; J Chang-Claude; U Bolm-Audorff; K H Jöckel; F Donato; C Serra; J Wahrendorf; M Hours; A T'Mannetje; M Kogevinas; P Boffetta
Journal:  Int J Cancer       Date:  2000-04-15       Impact factor: 7.396

2.  Cigarette smoking and testicular cancer.

Authors:  Anil Srivastava; Nancy Kreiger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-01       Impact factor: 4.254

3.  Smoking cessation and renal cell carcinoma.

Authors:  Alexander S Parker; James R Cerhan; Carol A Janney; Charles F Lynch; Kenneth P Cantor
Journal:  Ann Epidemiol       Date:  2003-04       Impact factor: 3.797

4.  Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease.

Authors:  Janet R Daling; Margaret M Madeleine; Lisa G Johnson; Stephen M Schwartz; Katherine A Shera; Michelle A Wurscher; Joseph J Carter; Peggy L Porter; Denise A Galloway; James K McDougall; John N Krieger
Journal:  Int J Cancer       Date:  2005-09-10       Impact factor: 7.396

5.  Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies.

Authors:  Jay D Hunt; Olga L van der Hel; Garnett P McMillan; Paolo Boffetta; Paul Brennan
Journal:  Int J Cancer       Date:  2005-03-10       Impact factor: 7.396

6.  Are patients aware of the association between smoking and bladder cancer?

Authors:  Alan M Nieder; Seeniann John; Catherine R Messina; Iris A Granek; Howard L Adler
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

7.  Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies.

Authors:  Michael Huncharek; K Sue Haddock; Rodney Reid; Bruce Kupelnick
Journal:  Am J Public Health       Date:  2009-07-16       Impact factor: 9.308

8.  Cigarette smoking and risk of prostate cancer in middle-aged men.

Authors:  Lora A Plaskon; David F Penson; Thomas L Vaughan; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-07       Impact factor: 4.254

Review 9.  The health economics of bladder cancer: a comprehensive review of the published literature.

Authors:  Marc F Botteman; Chris L Pashos; Alberto Redaelli; Benjamin Laskin; Robert Hauser
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Cigarette smoking and the risk of anogenital cancer.

Authors:  J R Daling; K J Sherman; T G Hislop; C Maden; M T Mandelson; A M Beckmann; N S Weiss
Journal:  Am J Epidemiol       Date:  1992-01-15       Impact factor: 4.897

View more
  3 in total

1.  Knowledge of smoking as a risk factor for disease among urology clinic patients in Australia.

Authors:  Munad Khan; Nathan Papa; Todd Manning; Tatenda Nzenza; Lauren Simionato; Nathan Lawrentschuk
Journal:  World J Urol       Date:  2018-03-27       Impact factor: 4.226

2.  Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guérin Treatment.

Authors:  Andrew T Lenis; Kian Asanad; Maher Blaibel; Nicholas M Donin; Karim Chamie
Journal:  Urol Pract       Date:  2017-03-02

3.  Associations of urological malignancies with renal progression and mortality in advanced chronic kidney disease: a propensity-matched cohort study.

Authors:  Rajkumar Chinnadurai; Noel W Clarke; Philip A Kalra
Journal:  BMC Nephrol       Date:  2020-05-29       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.